Robinson Capital Management’s Aspire Biopharma ASBP Stock Holding History

Robinson Capital Management’s Portfolio ASBP Stock Details ASBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-4	Closed	-$55.7K	–	183
2024 Q3	$55.7K	Buy	+4	New	+$54.4K	0.02%	143
2024 Q2	–	Sell	-8	Closed	-$114K	–	216
2024 Q1	$114K	Sell	8 -1	-11%	-$13.2K	0.04%	132
2023 Q4	$114K	Hold	9	–	–	0.04%	136
2023 Q3	$130K	Buy	9 +6	+200%	+$77.4K	0.06%	141
2023 Q2	$33.7K	Buy	+3	New	+$37.7K	0.02%	166

Other funds holding ASBP

HCI

Harraden Circle Investments New York $499M AUM 24.03% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Robinson Capital Management's ASBP Position: Q4 2024 in Review

Robinson Capital Management sold out of Aspire Biopharma (ASBP) in Q4 2024, closing a stake of 4 shares — an estimated $55.7K sold.

Robinson Capital Management first reported a position in ASBP in Q2 2023 and held it in 5 quarters. The position peaked at $130K in Q3 2023. 2 funds tracked by Wall St. Rank hold ASBP as of Q4 2024.

Robinson Capital Management reported no remaining Aspire Biopharma position as of Q4 2024 after selling out during the quarter.
Robinson Capital Management sold 4 Aspire Biopharma shares in Q4 2024, an estimated $55.7K.
Robinson Capital Management first reported a position in Aspire Biopharma in Q2 2023 and held it in 5 quarters.
Robinson Capital Management's Aspire Biopharma position peaked at $130K in Q3 2023.
2 funds tracked by Wall St. Rank held Aspire Biopharma as of Q4 2024.

Based on Robinson Capital Management's 13F filing for Q4 2024, filed 31 Jan 2025.